Rajesh Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 02-07-2024
- Paid Up Capital ₹ 0.10 M
as on 02-07-2024
- Company Age 26 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 18.20 M
as on 02-07-2024
- Satisfied Charges ₹ 3.00 M
as on 02-07-2024
- Revenue 2.39%
(FY 2023)
- Profit -13.21%
(FY 2023)
- Ebitda -8.36%
(FY 2023)
- Net Worth 3.52%
(FY 2023)
- Total Assets 16.28%
(FY 2023)
About Rajesh Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.82 Cr. The company has closed loans amounting to ₹3.00 M, as per Ministry of Corporate Affairs (MCA) records.
Rajesh Gupta, Babu Gupta, Abhay Kotwal, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232RJ1998PTC015062
- Company No.
015062
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Aug 1998
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Alwar, Rajasthan, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Rajesh Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Akshay Kotwal  | Director | 11-Jan-2019 | Current |
| Rajesh Gupta | Director | 28-Aug-1998 | Current |
| Babu Gupta | Director | 28-Aug-1998 | Current |
| Abhay Kotwal | Director | 11-Jan-2019 | Current |
Financial Performance and Corporate Structure Insights of Rajesh Pharma.
Rajesh Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.39% increase. The company also saw a substantial fall in profitability, with a 13.21% decrease in profit. The company's net worth moved up by a moderate rise of 3.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rajesh Pharma?
In 2023, Rajesh Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 30 May 2022 | ₹0.55 M | Open |
Others Creation Date: 03 Sep 2011 | ₹1.67 Cr | Open |
Union Bank Of India Creation Date: 17 Jan 2011 | ₹0.44 M | Open |
How Many Employees Work at Rajesh Pharma?
Unlock and access historical data on people associated with Rajesh Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rajesh Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rajesh Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
